Key facts
- CytoRecovery’s last known valuation is $11.0M (Oct 2023).
- It has raised $11.2M across 3 recorded rounds; the latest was Seed Round ($2.1M) in Jul 2022.
- Notable investors include US National Science Foundation, MedTech Innovator, Keiretsu Forum, Virginia Innovation Partnership Corporation, Virginia Venture Partners — 15 tracked in total.
- CytoRecovery has filed 5 Form Ds with the SEC since 2019, most recently Jul 2022 ($2.1M sold to 24 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for CytoRecovery
Funding rounds
3 roundsAbout CytoRecovery
Developer of microfluidic technology designed to recover biological cells from samples. The company's technology offers cell biology analytics, individual trapping, and release of rare cell populations for downstream analysis, enabling biologists to select and separate rare, homogeneous, viable cell subpopulations from tissue, blood, and other biological samples.
- Sector
- Healthcare
- HQ
- Blacksburg, VA, United States
- Founded
- 2017
- Employees
- 7
- Website
- cytorecovery.com/
- Ownership
- Privately Held (backing)
CytoRecovery doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CytoRecovery shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CytoRecovery in its N-PORT filings yet. We sweep new filings monthly.